The 3MG trial: magnesium in asthma


The 3MG trial compared intravenous and nebulised magnesium sulphate against placebo in addition to standard treatment in moderate to severe asthma. Notably, the trial excluded life-threatening asthma—the group we are most likely to be using magnesium in.

At the end of the day (and trial), they found no benefit with either IV or nebulised magnesium for the primary endpoints of admission to hospital within 7 days and breathlessness.

Here is our Journal Club review of this article from August, for the FOAM world to enjoy. Thanks!

Share your thoughts